482 results on '"Babjuk, Marko"'
Search Results
52. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2
53. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
54. Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer
55. IMPACT OF SYNCHRONOUS BLADDER CANCER ON RECURRENCE-FREE SURVIVAL AFTER SURGICAL TREATMENT FOR PRIMARY URETHRAL CANCER: RESULTS FROM THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMA (ICPUC): MP13-03
56. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
57. Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder
58. Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”
59. Gene Expression Analysis for the Prediction of Recurrence in Patients with Primary Ta Urothelial Cell Carcinoma
60. IMAGINE—IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines
61. Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study
62. Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes
63. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy
64. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy
65. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer
66. Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer
67. VALIDATION OF VISCERAL METASTASES AND KARNOFSKY PERFORMANCE STATUS SCORE AS PREDICTORS OF ALL CAUSE MORTALITY AND CANCER-SPECIFIC SURVIVAL: 394
68. Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial
69. Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
70. Preoperative Prostate Health Index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer.
71. Reply to Can Lu and Xiao Guan’s Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022
72. Unanswered Questions for Bladder Tumours Unresponsive to Bacillus Calmette-Guérin
73. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer
74. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments?
75. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
76. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer
77. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer
78. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer
79. Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial
80. Is Engrailed-2 (EN2) a truly promising biomarker in prostate cancer detection?
81. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
82. Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non–muscle-invasive Bladder Cancer on Tumor Recurrence
83. MATURITION OF THE ORTHOTOPIC BLADDER REPLACEMENT IN THE FEMALE
84. Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.
85. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer.
86. Is Engrailed-2 (EN2) a truly promising biomarker in prostate cancer detection?
87. T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues
88. A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens
89. Bladder Cancer in the Elderly
90. The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma
91. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update
92. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma
93. Novinky z konference KNOU 2021.
94. Editorial Comment
95. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non–muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447–61
96. Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052–68
97. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
98. Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy
99. Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?
100. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.